Concert Pharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Concert Pharma (CNCE) Reports Q1 Loss of $0.93/Share
May 2, 2019 7:44 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.93), versus ($0.19) reported last year. Revenue for the quarter came in at $1 million, versus $10.48 million reported last year.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More